Partial restoration of brain dystrophin by tricyclo-DNA antisense oligonucleotides alleviates emotional deficits in mdx52 mice

Archive ouverte

Saoudi, Amel | Barberat, Sacha | Le Coz, Olivier | Vacca, Ophélie | Doisy Caquant, Mathilde | Tensorer, Thomas | Sliwinski, Eric | Garcia, Luis | Muntoni, Francesco M. | Vaillend, Cyrille | Goyenvalle, Aurélie

Edité par CCSD ; Elsevier -

International audience. The mdx52 mouse model recapitulates a frequent mutation profile associated with brain involvement in Duchenne muscular dystrophy. Deletion of exon 52 impedes expression of two dystrophins (Dp427, Dp140) expressed in brain, and is eligible for therapeutic exon-skipping strategies. We previously showed that mdx52 mice display enhanced anxiety and fearfulness, and impaired associative fear learning. In this study, we examined the reversibility of these phenotypes using exon 51 skipping to restore exclusively Dp427 expression in the brain of mdx52 mice. We first show that a single intracerebroventricular administration of tricyclo-DNA antisense oligonucleotides targeting exon 51 restores 5%–15% of dystrophin protein expression in the hippocampus, cerebellum, and cortex, at stable levels between 7 and 11 week after injection. Anxiety and unconditioned fear were significantly reduced in treated mdx52 mice and acquisition of fear conditioning appeared fully rescued, while fear memory tested 24 h later was only partially improved. Additional restoration of Dp427 in skeletal and cardiac muscles by systemic treatment did not further improve the unconditioned fear response, confirming the central origin of this phenotype. These findings indicate that some emotional and cognitive deficits associated with dystrophin deficiency may be reversible or at least improved by partial postnatal dystrophin rescue.

Suggestions

Du même auteur

Investigating the Impact of Delivery Routes for Exon Skipping Therapies in the CNS of DMD Mouse Models

Archive ouverte | Saoudi, Amel | CCSD

International audience. Nucleic acid-based therapies have demonstrated great potential for the treatment of monogenetic diseases, including neurologic disorders. To date, regulatory approval has been received for a ...

Networking to Optimize Dmd exon 53 Skipping in the Brain of mdx52 Mouse Model

Archive ouverte | Doisy, Mathilde | CCSD

International audience. Duchenne muscular dystrophy (DMD) is caused by mutations in the DMD gene that disrupt the open reading frame and thus prevent production of functional dystrophin proteins. Recent advances in ...

Valproic Acid Improves Antisense-Mediated Exon-Skipping Efficacy in mdx Mice

Archive ouverte | Phongsavanh, Micky | CCSD

International audience. Duchenne muscular dystrophy (DMD) is a severe genetic disorder characterized by the progressive degeneration of skeletal and cardiac muscles due to the absence of dystrophin. Exon-skipping th...

Chargement des enrichissements...